Machine Learning and Multimodal Biomarker Discovery in Alzheimer’s Disease

Background/Objectives: The accelerating integration of machine learning (ML) with molecular, imaging, and physiological data is transforming Alzheimer’s disease (AD) research. Methods & Results: Recent studies demonstrate that multimodal, AI-assisted platforms can enhance early diagnosis, predict biomarker trajectories, and identify novel therapeutic targets. This mini-review covers the evolving AD diagnostic and biomarker frameworks, current therapeutic strategies including recently approved anti-amyloid immunotherapies, and advances from contemporary studies employing ML across diverse data streams, ranging from cerebrospinal fluid (CSF) and plasma proteomics to Raman spectroscopy, neuroimaging, transcriptomics, and microbiome signatures. Conclusions: Collectively, they illustrate how artificial intelligence (AI) has shifted A biomarker discovery from univariate to network-based inference, achieving clinically relevant accuracy while emphasizing model interpretability. We discuss biological insights, translational implications, and persisting challenges related to validation, bias, and regulatory integration.